Modalis Therapeutics Reports Loss Due to Electronic Fraud Incident
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation announced a special loss due to an electronic fraud incident at its U.S. subsidiary, resulting in a net loss of 90,000 USD. The company has taken steps to prevent future occurrences, including enhancing security measures and strengthening payment processes, while assuring stakeholders of their commitment to risk management.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a pioneering company listed on the Tokyo Stock Exchange, focusing on developing innovative treatments for rare genetic diseases using its proprietary CRISPR-GNDM epigenome editing technology.
YTD Price Performance: 0.0%
Average Trading Volume: 15,110,181
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.08B
See more insights into 4883 stock on TipRanks’ Stock Analysis page.
Trending Articles
